Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

This study has been completed.
Information provided by:
Novartis Identifier:
First received: August 24, 2005
Last updated: February 24, 2011
Last verified: February 2011

The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.

Condition Intervention Phase
Drug: aliskiren
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 4 Month Extension to a 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long-term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Assessment of safety through reporting of adverse events and serious adverse events, including deaths, following a 12 month study

Secondary Outcome Measures:
  • Change from baseline (following a 12 month study) in mean sitting diastolic blood pressure after 4 months
  • Change from baseline (following a 12 month study) in mean sitting systolic blood pressure after 4 months
  • Change from baseline (following a 12 month study) in mean standing blood pressure after 4 months
  • Diastolic blood pressure less than 90 mmHg or 10 mmHg or greater change from baseline
  • Blood pressure less than 140/90 mmHg

Estimated Enrollment: 250
Study Start Date: June 2005
Study Completion Date: February 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. their successful completion of the CSPP100A2302 core study with at least eight months combination treatment of aliskiren 300 mg and HCTZ 25 mg, i.e., patients who received aliskiren 300 mg and HCTZ 25 mg at Month 4 of the core study and complete the core study.
  2. absence of ongoing severe adverse events at Visit 10.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00171405

United States, New Jersey
Investigative Site
East Hanover, New Jersey, United States
Investigative Site
Deurne, Belgium
Investigative Site
Ste-Fov, Canada
Investigative Site
Krassel, Germany
Investigative Site
Broni, Italy
Investigative Site
Rotterdam, Netherlands
Investigative Site
Lima, Peru
Russian Federation
Investigative Site
Moscow, Russian Federation
Investigative Site
Basel, Switzerland
United Kingdom
Investigative Site
London, United Kingdom
Sponsors and Collaborators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided Identifier: NCT00171405     History of Changes
Other Study ID Numbers: CSPP100A2302E1
Study First Received: August 24, 2005
Last Updated: February 24, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases
Antihypertensive Agents
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Therapeutic Uses processed this record on November 25, 2014